Skip to content
Inciteful Med

Beyond Skin and Muscle: Lung and Systemic Complications

Last updated:

Dermatomyositis can cause serious internal complications, including interstitial lung disease (ILD) and swallowing difficulties (dysphagia). Your specific autoantibodies, such as anti-MDA5 or anti-Jo-1, can help predict your risk for lung disease and guide preventative care.

Key Takeaways

  • • Dermatomyositis can cause interstitial lung disease (ILD), which leads to inflammation and scarring in the lungs.
  • • Your autoantibody profile, such as having anti-MDA5 or anti-Jo-1, helps predict your risk for chronic or rapidly progressive lung disease.
  • • Patients taking immunosuppressants are at risk for PJP pneumonia and may need preventative antibiotics like Bactrim.
  • • Dermatomyositis can weaken throat muscles, leading to difficulty swallowing (dysphagia) and increasing the risk of aspiration pneumonia.
  • • Specialized evaluations like a FEES test can monitor swallowing function to ensure you are eating and drinking safely.

While dermatomyositis (DM) is often recognized for its skin and muscle symptoms, it can also affect the internal organs. Understanding these potential complications—particularly those involving the lungs and the swallowing muscles—is essential for early detection and effective management [1][2].

Interstitial Lung Disease (ILD)

Interstitial Lung Disease (ILD) is a condition where the tissues of the lungs become inflamed or scarred, making it difficult for the lungs to provide enough oxygen to the body [3]. In dermatomyositis, ILD generally falls into two categories based on how quickly it progresses.

Chronic vs. Rapidly Progressive ILD

The type of lung involvement you might experience is often predicted by your specific autoantibody profile [4][5].

  • Chronic ILD: This is most commonly associated with anti-synthetase antibodies (such as anti-Jo-1) [3][5]. Chronic ILD typically develops slowly over months or years, causing a persistent dry cough and gradual shortness of breath during exercise [6]. While serious, it often responds to long-term maintenance therapy [6].
  • Rapidly Progressive ILD (RP-ILD): This is a medical emergency primarily seen in patients with the anti-MDA5 antibody [4][7]. RP-ILD can cause lung function to decline significantly within days or weeks [3]. Patients often require immediate hospitalization and aggressive “triple-drug” therapy to halt the inflammation before permanent scarring occurs [8][6].

Infection Risks and Prevention

The medications used to treat DM work by suppressing the immune system. While this stops the attack on your lungs and muscles, it also makes you more vulnerable to opportunistic infections—infections that a healthy immune system would normally easily fight off [9][10].

  • PJP Pneumonia: A serious fungal infection called Pneumocystis jirovecii pneumonia (PJP) is a major risk for DM patients on high-dose steroids or combined immunosuppressants [11][9]. This risk is especially high in patients with the anti-MDA5 antibody or low white blood cell counts (lymphopenia) [11][12].
  • Prophylaxis: To prevent PJP, many doctors prescribe a daily or three-times-weekly “prophylactic” antibiotic, such as Bactrim (trimethoprim-sulfamethoxazole) [13][14]. (If you have a sulfa allergy, your doctor can prescribe alternative preventative medications like atovaquone or dapsone). Taking this preventative medication is one of the most effective ways to reduce the risk of life-threatening pneumonia during treatment [13].

Dysphagia and Swallowing Safety

Dysphagia, or difficulty swallowing, occurs when the muscles in the throat and esophagus become weakened by the disease [15][16]. This is more than just an inconvenience; it can lead to several dangerous secondary complications:

  • Aspiration Pneumonia: If the throat muscles are weak, food or liquid can accidentally enter the airway (aspiration) rather than the stomach [15]. This can cause a severe lung infection known as aspiration pneumonia [15].
  • Malnutrition and Dehydration: If swallowing is painful or difficult, patients may naturally eat or drink less, leading to significant weight loss and nutrient deficiencies [16].

Early recognition of swallowing issues is critical. Your doctor may recommend a specialized test, such as a Flexible Endoscopic Evaluation of Swallowing (FEES), to visualize how well your throat muscles are working and ensure you are eating and drinking safely [15].

Frequently Asked Questions

How does dermatomyositis affect the lungs?
Dermatomyositis can cause interstitial lung disease (ILD), a condition where lung tissue becomes inflamed or scarred. This makes it difficult for your lungs to provide enough oxygen to your body, often resulting in a persistent dry cough and shortness of breath.
What is the difference between chronic and rapidly progressive ILD?
Chronic ILD develops slowly over months or years and is often linked to anti-synthetase antibodies like anti-Jo-1. Rapidly progressive ILD (RP-ILD) is a severe medical emergency that can reduce lung function within days or weeks, frequently associated with the anti-MDA5 antibody.
Why might my doctor prescribe an antibiotic like Bactrim for dermatomyositis?
Immunosuppressant medications used to treat dermatomyositis lower your immune defenses, making you vulnerable to opportunistic infections like PJP pneumonia. Preventative antibiotics such as Bactrim help protect you from these dangerous lung infections while you undergo treatment.
What are the signs of swallowing problems in dermatomyositis?
Warning signs include frequent coughing or clearing of the throat while eating or drinking, a feeling that food is stuck in your chest, and unexplained weight loss. If you notice these symptoms, it is important to tell your doctor right away.
Why is difficulty swallowing dangerous?
When throat muscles are weakened by dermatomyositis, food or liquid can accidentally enter your airway instead of your stomach. This can lead to a severe and potentially life-threatening lung infection known as aspiration pneumonia.

Questions for Your Doctor

  • • Which antibody profile do I have (like anti-MDA5 or anti-Jo-1), and how does that affect my risk for lung disease?
  • • Should I be taking a preventative antibiotic like Bactrim to protect against PJP pneumonia while I am on immunosuppressants?
  • • What are the early warning signs of lung involvement that I should watch for at home?
  • • Can we perform a baseline swallowing evaluation (like a FEES or barium swallow) to ensure I am not at risk for aspiration?
  • • If I develop a cough or shortness of breath, what is the fastest way to get evaluated for RP-ILD?

Questions for You

  • • Have you noticed any new or worsening shortness of breath while doing simple tasks, like walking or climbing stairs?
  • • Do you have a persistent dry cough that doesn't seem to go away?
  • • Do you find yourself coughing or clearing your throat frequently while eating or drinking?
  • • Have you experienced any unintended weight loss or a feeling that food is getting "stuck" in your chest?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    A Diagnostic Delay: Respiratory Muscle Weakness in Dermatomyositis Masquerading as Pneumonia.

    Jain M, Doddapaneni VK, Rahman B, Aslam N

    Cureus 2025; (17(12)):e100112 doi:10.7759/cureus.100112.

    PMID: 41589189
  2. 2

    [New insights of myositis-specific and -associated autoantibodies in juvenile and adult type myositis].

    Váncsa A, Dankó K

    Orvosi hetilap 2016; (157(30)):1179-84 doi:10.1556/650.2016.30404.

    PMID: 27452067
  3. 3

    Clinical Features of Anti-MDA5 Antibody-positive Rapidly Progressive Interstitial Lung Disease without Signs of Dermatomyositis.

    Sakamoto N, Ishimoto H, Nakashima S, et al.

    Internal medicine (Tokyo, Japan) 2019; (58(6)):837-841 doi:10.2169/internalmedicine.1516-18.

    PMID: 30449789
  4. 4

    Clinical characteristics of anti-MDA5 antibody-positive interstitial lung disease.

    Kaenmuang P, Navasakulpong A

    Respirology case reports 2021; (9(1)):e00701 doi:10.1002/rcr2.701.

    PMID: 33343905
  5. 5

    Biomarkers and Autoantibodies of Interstitial Lung Disease with Idiopathic Inflammatory Myopathies.

    Yoshifuji H

    Clinical medicine insights. Circulatory, respiratory and pulmonary medicine 2015; (9(Suppl 1)):141-6 doi:10.4137/CCRPM.S36748.

    PMID: 27081322
  6. 6

    Management of Myositis-Associated Interstitial Lung Disease.

    Fujisawa T

    Medicina (Kaunas, Lithuania) 2021; (57(4)) doi:10.3390/medicina57040347.

    PMID: 33916864
  7. 7

    Amyopathic Dermatomyositis with a Rapidly Progressing Interstitial Pneumonia.

    Logvinova D, Žentiņa D, Ivanova K, et al.

    European journal of case reports in internal medicine 2024; (11(12)):005036 doi:10.12890/2024_005036.

    PMID: 39790853
  8. 8

    Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease.

    Motegi SI, Sekiguchi A, Toki S, et al.

    European journal of dermatology : EJD 2019; (29(5)):511-517 doi:10.1684/ejd.2019.3634.

    PMID: 31617496
  9. 9

    Pneumocystis jirovecii Pneumonia and Other Infections in Idiopathic Inflammatory Myositis.

    Mecoli CA, Danoff SK

    Current rheumatology reports 2020; (22(2)):7 doi:10.1007/s11926-020-0883-0.

    PMID: 32020305
  10. 10

    Rehospitalization to evaluate outcomes during clinical courses in patients with elderly-onset idiopathic inflammatory myositis: a retrospective single-center study.

    Kurashina JI, Shimojima Y, Kishida D, et al.

    Clinical rheumatology 2025; (44(8)):3245-3251 doi:10.1007/s10067-025-07540-7.

    PMID: 40560308
  11. 11

    Analysis of clinical features and risk factors for patients with idiopathic inflammatory myopathy complicated by Pneumocystis jirovecii pneumonia.

    Li J, Huang W, Ren F, et al.

    Clinical and experimental rheumatology 2026; (44(2)):210-217 doi:10.55563/clinexprheumatol/fpbkc8.

    PMID: 40470565
  12. 12

    Clinical characteristics of and risk factors for Pneumocystis jirovecii pneumonia in anti-melanoma differentiation-associated gene 5 (Anti-MDA5) antibody-positive dermatomyositis patients: a single-center retrospective study.

    Li J, Wang S, Zheng J, et al.

    Clinical rheumatology 2023; (42(2)):453-462 doi:10.1007/s10067-022-06403-9.

    PMID: 36301369
  13. 13

    Prophylactic Effect of Trimethoprim-sulfamethoxazole on Severe Infections in Idiopathic Inflammatory Myopathy.

    Kogami M, Abe Y, Ando T, et al.

    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2026; doi:10.1097/RHU.0000000000002325.

    PMID: 41730233
  14. 14

    Compounded sulfamethoxazole improved the prognosis of dermatomyositis patients positive with anti-melanoma differentiation-associated gene 5.

    Liu L, Zhang Y, Liu S, et al.

    Rheumatology (Oxford, England) 2023; (62(9)):3095-3100 doi:10.1093/rheumatology/kead034.

    PMID: 36702462
  15. 15

    Predictors, outcome and characteristics of oropharyngeal dysphagia in idiopathic inflammatory myopathy.

    Labeit B, Perlova K, Pawlitzki M, et al.

    Muscle & nerve 2021; (63(6)):874-880 doi:10.1002/mus.27225.

    PMID: 33711182
  16. 16

    Diagnostic challenges of dermatomyositis in a resource-limited setting: a case report.

    Alemu GS, Ambaye MT

    Journal of medical case reports 2025; (19(1)):478 doi:10.1186/s13256-025-05446-1.

    PMID: 41035049

This page provides educational information about systemic complications of dermatomyositis. Always consult your rheumatologist or pulmonologist for personalized advice on monitoring your lung and swallowing health.

Stay up to date

Get notified when new research about Dermatomyositis is published.

No spam. Unsubscribe anytime.